During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in ...

Neal Shore, MD, FACS, discussed a study on survival outcomes in metastatic castration-sensitive prostate cancer comparing ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

Mass spectrometry and machine learning show promise for early cancer detection and prognosis by analyzing metabolic signatures.

Alessandra Ferrajoli, MD, discusses the importance of supportive care in the management of patients with chronic lymphocytic ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

October 2024, saw significant FDA actions and clinical trial updates that shaped cancer treatment progress. Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority ...

Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the CARTITUDE-4 trial.

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...

Additionally, positive findings from trials like ADRIATIC (NCT03703297) and IMforte (NCT05091567) are further shaping ...

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.